CD19 and leukemia: Using a xenograft mouse model, anti-CD19 directed CAR T cells were shown to eliminate the CD19+ cancerous B cells, resulting in prolonged survival of this NSG leukemia xenograft model [59] and this set the basis for the first clinical trial and later on, approval of the first CAR T cell products by the FDA.